Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
22 janv. 2024 06h40 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
16 janv. 2024 06h40 HE
|
Cellectar Biosciences
Proprietary TAT Phospholipid Conjugate Demonstrates Potent Activity in Resistant Pancreatic Cancer Initiating IND-enabling Studies for First-in-Human Phase I Clinical Study FLORHAM PARK, N.J., Jan. ...
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
12 janv. 2024 06h44 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
11 janv. 2024 06h40 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
08 janv. 2024 06h30 HE
|
Cellectar Biosciences
Iopofosine tested in heavily pretreated multi-class refractory population with a median of four prior therapies and achieves 75.6% Overall Response Rate; 61% Major Response Rate (95% CI, 44.5%,...
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
03 janv. 2024 08h30 HE
|
Cellectar Biosciences
Management to host conference call on Monday, January 8, 2024, at 8:00 am ET Company also to present at the Biotech Showcase FLORHAM PARK, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Cellectar...
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
19 déc. 2023 08h30 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
12 déc. 2023 08h30 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
05 déc. 2023 08h30 HE
|
Cellectar Biosciences
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
02 nov. 2023 07h30 HE
|
Cellectar Biosciences
Reports Preliminary Financial Results for Third Quarter 2023 and Provides a Corporate Update Conference Call scheduled for today at 8:30 am Eastern Time FLORHAM PARK, N.J., Nov. 02, 2023 ...